Hoersholm; February 19, 2016 – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI’s spinout OV has in-licensed LiPlaCis.
Oncology Venture a spinout from MPI’s has today announced in-licensing of LiPlaCis(TM) from LiPlasome Pharma ApS, Denmark. LiPlaCis will be the first prospective trial using the Drug Response Predictor – DRP(TM) from MPI.
LiPlaCis(TM) – a liposomal formulation of cisplatin – is just finalizing the dose escalation part of a phase 1 study in solid tumors and is on the verge of moving into the extension phase where screened breast cancer patients with metastatic disease will be treated.
Using analysis of patients own biopsies by the DRP(TM) patients are screened beforehand for high likelihood of effect of the LiPlaCis(TM) drug. The DRP(TM) should thereby enable a high response rate and give breast cancer patients a new effective treatment opportunity.
“This is a key step for MPI – the team in OV has the last three years worked with MPI and LiPlasome on LiPlaCis(TM)”, Said Adjunct professor Peter Buhl Jensen, MD, PhD and CEO of MPI. “The MPI and OV teams know the project well and we trust that LiPlaCis(TM) can by the use of the MPI DRP(TM) be developed into a new effective treatment opportunity for breast cancer patients”, Dr. Buhl Jensen further commented.”
For further information, please contact
CEO Peter Buhl Jensen, Adjunct professor, MD, PhD
Telephone: +45 21 60 89 22
E-mail: [email protected]
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. This DRP(TM) method builds on the comparison of sensitive and resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messenger RNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.
e-mail: [email protected]
Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
